Fig. 2From: Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trialTTF on-treatment CVAESI and hospitalized or fatal CVAESI. a. FF/UMEC/VI versus FF/VI and UMEC/VI. b. UMEC/VI versus FF/VI. Hospitalized or fatal CVAESI refers to any CVAESI that resulted in hospitalization/prolonged hospitalization or death. CI, confidence interval; CVAESI, cardiovascular adverse event of special interest; FF, fluticasone furoate; n, number of patients with an event; N, number of patients in subgroup; TTF, time to first; UMEC, umeclidinium; VI, vilanterolBack to article page